Ruby Ghadially
Research Subjects
Ruby Ghadially has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Lili Yue
Department of Dermatology, University of California San Francisco, San Francisco, California, USA
6 shared publicationsAlexandra Charruyer
Center of Regeneration Medicine and Stem Cell Research, University of California, Veterans Affairs Medical Center
5 shared publicationsLauren R. Strachan
Department of Dermatology, University of California San Francisco and Veteran Affairs Medical Center, Dermatology Service, San Francisco, California, USA
5 shared publicationsStephen Fong
Department of Dermatology, University of California San Francisco, San Francisco, California, USA
3 shared publicationsKenneth J. Scalapino
Division of Rheumatology, Department of Medicine, University of California, San Francisco and San Francisco Veterans Affairs Medical Center, San Francisco, California, USA
2 shared publicationsMaria L. Mancianti
Department of Pathology, Alta Bates Medical Center, Berkeley, California, USA
2 shared publications
Latest Publications
- 27 June 2017
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 35 (8) , 2001-2007
Brief Report: Interleukin-17A-Dependent Asymmetric Stem Cell Divisions Are Increased in Human Psoriasis: A Mechanism Underlying Benign Hyperproliferation
The balance between asymmetric and symmetric stem cell (SC) divisions is key to tissue homeostasis, and dysregulation of this balance has been shown in cancers. We hypothesized that the balance between asymmetric cell divisions (ACDs) and symmetric cell divisions (SCDs) would be dysregulated in the benign hyperproliferation of psoriasis. We found that, while SCDs were increased in squamous cell carcinoma (SCC) (human and murine), ACDs were increased in the benign hyperproliferation of psoriasis (human and murine). Furthermore, while sonic hedgehog (linked to human cancer) and pifithrinα (p53 inhibitor) promoted SCDs, interleukin (IL)-1α and amphiregulin (associated with benign epidermal hyperproliferation) promoted ACDs. While there was dysregulation of the ACD:SCD ratio, no change in SC frequency was detected in epidermis from psoriasis patients, or in human keratinocytes treated with IL-1α or amphiregulin. We investigated the mechanism whereby immune alterations of psoriasis result in ACDs. IL17 inhibitors are effective new therapies for psoriasis. We found that IL17A increased ACDs in human keratinocytes. Additionally, studies in the imiquimod-induced psoriasis-like mouse model revealed that ACDs in psoriasis are IL17A-dependent. In summary, our studies suggest an association between benign hyperproliferation and increased ACDs. This work begins to elucidate the mechanisms by which immune alteration can induce keratinocyte hyperproliferation. Altogether, this work affirms that a finely tuned balance of ACDs and SCDs is important and that manipulating this balance may constitute an effective treatment strategy for hyperproliferative diseases.
- 27 June 2017
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 35 (8) , 2001-2007
Brief Report: Interleukin-17A-Dependent Asymmetric Stem Cell Divisions Are Increased in Human Psoriasis: A Mechanism Underlying Benign Hyperproliferation
The balance between asymmetric and symmetric stem cell (SC) divisions is key to tissue homeostasis, and dysregulation of this balance has been shown in cancers. We hypothesized that the balance between asymmetric cell divisions (ACDs) and symmetric cell divisions (SCDs) would be dysregulated in the benign hyperproliferation of psoriasis. We found that, while SCDs were increased in squamous cell carcinoma (SCC) (human and murine), ACDs were increased in the benign hyperproliferation of psoriasis (human and murine). Furthermore, while sonic hedgehog (linked to human cancer) and pifithrinα (p53 inhibitor) promoted SCDs, interleukin (IL)-1α and amphiregulin (associated with benign epidermal hyperproliferation) promoted ACDs. While there was dysregulation of the ACD:SCD ratio, no change in SC frequency was detected in epidermis from psoriasis patients, or in human keratinocytes treated with IL-1α or amphiregulin. We investigated the mechanism whereby immune alterations of psoriasis result in ACDs. IL17 inhibitors are effective new therapies for psoriasis. We found that IL17A increased ACDs in human keratinocytes. Additionally, studies in the imiquimod-induced psoriasis-like mouse model revealed that ACDs in psoriasis are IL17A-dependent. In summary, our studies suggest an association between benign hyperproliferation and increased ACDs. This work begins to elucidate the mechanisms by which immune alteration can induce keratinocyte hyperproliferation. Altogether, this work affirms that a finely tuned balance of ACDs and SCDs is important and that manipulating this balance may constitute an effective treatment strategy for hyperproliferative diseases.
- 23 December 2015
- Published by Springer Nature
- p. 1-14
Aging of Epidermal Stem Cells
- 1 April 2015
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 25 (2) , 138-148
Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma
Cells with aldehyde dehydrogenase activity (ALDH+) are the most tumorigenic cells in many cancers, including melanoma, making ALDH a candidate therapeutic target. We examined the effects of chemical inhibition of ALDH1 on the response of human melanoma xenografts to chemotherapy and the effects of ALDH1A1 RNA silencing on melanoma growth and metastasis. Addition of ALDH1 inhibitors (e.g. diethylaminobenzaldehyde) to dacarbazine chemotherapy, not only reduced tumor growth in vivo, but also resulted in a significant decrease in the number of residual cells capable of tumorigenesis. shRNA depletion of ALDH1A1 in melanoma cells resulted not only in a significant delay in appearance of xenograft melanomas and reduction in growth, but also significantly decreased the number of metastases and metastatic burden after lateral tail vein injections in mice. In summary, ALDH1 inhibition in combinatorial therapy with dacarbazine reduced the number of residual tumorigenic cells post-therapy and ALDH1A1 depletion had marked inhibitory effects on both melanoma growth and metastasis. These findings suggest that ALDH1 inhibition may not only be able to provide a therapeutic advantage in melanoma treatment, but may also prevent rapid relapse after therapy, as residual tumorigenic cells are fewer and metastatic ability is diminished.
- 1 April 2015
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 25 (2) , 138-148
Targeting ALDH1 to decrease tumorigenicity, growth and metastasis of human melanoma
Cells with aldehyde dehydrogenase activity (ALDH+) are the most tumorigenic cells in many cancers, including melanoma, making ALDH a candidate therapeutic target. We examined the effects of chemical inhibition of ALDH1 on the response of human melanoma xenografts to chemotherapy and the effects of ALDH1A1 RNA silencing on melanoma growth and metastasis. Addition of ALDH1 inhibitors (e.g. diethylaminobenzaldehyde) to dacarbazine chemotherapy, not only reduced tumor growth in vivo, but also resulted in a significant decrease in the number of residual cells capable of tumorigenesis. shRNA depletion of ALDH1A1 in melanoma cells resulted not only in a significant delay in appearance of xenograft melanomas and reduction in growth, but also significantly decreased the number of metastases and metastatic burden after lateral tail vein injections in mice. In summary, ALDH1 inhibition in combinatorial therapy with dacarbazine reduced the number of residual tumorigenic cells post-therapy and ALDH1A1 depletion had marked inhibitory effects on both melanoma growth and metastasis. These findings suggest that ALDH1 inhibition may not only be able to provide a therapeutic advantage in melanoma treatment, but may also prevent rapid relapse after therapy, as residual tumorigenic cells are fewer and metastatic ability is diminished.
- Open Access
- 24 March 2013
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 31 (4) , 786-799
The CD44+ALDH+ Population of Human Keratinocytes Is Enriched for Epidermal Stem Cells with Long-Term Repopulating Ability
Like for other somatic tissues, isolation of a pure population of stem cells has been a primary goal in epidermal biology. We isolated discrete populations of freshly obtained human neonatal keratinocytes (HNKs) using previously untested candidate stem cell markers aldehyde dehydrogenase (ALDH) and CD44 as well as the previously studied combination of integrin α6 and CD71. An in vivo transplantation assay combined with limiting dilution analysis was used to quantify enrichment for long-term repopulating cells in the isolated populations. The ALDH+CD44+ population was enriched 12.6-fold for long-term repopulating epidermal stem cells (EpiSCs) and the integrin α6hiCD71lo population was enriched 5.6-fold, over unfractionated cells. In addition to long-term repopulation, CD44+ALDH+ keratinocytes exhibited other stem cell properties. CD44+ALDH+ keratinocytes had self-renewal ability, demonstrated by increased numbers of cells expressing nuclear Bmi-1, serial transplantation of CD44+ALDH+ cells, and holoclone formation in vitro. CD44+ALDH+ cells were multipotent, producing greater numbers of hair follicle-like structures than CD44−ALDH− cells. Furthermore, 58% ± 7% of CD44+ALDH+ cells exhibited label-retention. In vitro, CD44+ALDH+ cells showed enhanced colony formation, in both keratinocyte and embryonic stem cell growth media. In summary, the CD44+ALDH+ population exhibits stem cell properties including long-term epidermal regeneration, multipotency, label retention, and holoclone formation. This study shows that it is possible to quantify the relative number of EpiSCs in human keratinocyte populations using long-term repopulation as a functional test of stem cell nature. Future studies will combine isolation strategies as dictated by the results of quantitative transplantation assays, in order to achieve a nearly pure population of EpiSCs. STEM CELLS 2013;31:786–799
- 24 March 2013
- Published by Oxford University Press (OUP) in Stem Cells
- Vol. 31 (4) , 786-799
Open AccessThe CD44+ALDH+ Population of Human Keratinocytes Is Enriched for Epidermal Stem Cells with Long-Term Repopulating Ability
Like for other somatic tissues, isolation of a pure population of stem cells has been a primary goal in epidermal biology. We isolated discrete populations of freshly obtained human neonatal keratinocytes (HNKs) using previously untested candidate stem cell markers aldehyde dehydrogenase (ALDH) and CD44 as well as the previously studied combination of integrin α6 and CD71. An in vivo transplantation assay combined with limiting dilution analysis was used to quantify enrichment for long-term repopulating cells in the isolated populations. The ALDH+CD44+ population was enriched 12.6-fold for long-term repopulating epidermal stem cells (EpiSCs) and the integrin α6hiCD71lo population was enriched 5.6-fold, over unfractionated cells. In addition to long-term repopulation, CD44+ALDH+ keratinocytes exhibited other stem cell properties. CD44+ALDH+ keratinocytes had self-renewal ability, demonstrated by increased numbers of cells expressing nuclear Bmi-1, serial transplantation of CD44+ALDH+ cells, and holoclone formation in vitro. CD44+ALDH+ cells were multipotent, producing greater numbers of hair follicle-like structures than CD44−ALDH− cells. Furthermore, 58% ± 7% of CD44+ALDH+ cells exhibited label-retention. In vitro, CD44+ALDH+ cells showed enhanced colony formation, in both keratinocyte and embryonic stem cell growth media. In summary, the CD44+ALDH+ population exhibits stem cell properties including long-term epidermal regeneration, multipotency, label retention, and holoclone formation. This study shows that it is possible to quantify the relative number of EpiSCs in human keratinocyte populations using long-term repopulation as a functional test of stem cell nature. Future studies will combine isolation strategies as dictated by the results of quantitative transplantation assays, in order to achieve a nearly pure population of EpiSCs. STEM CELLS 2013;31:786–799
- 1 November 2012
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 132 (11) , 2522-2533
CD133 Is a Marker for Long-Term Repopulating Murine Epidermal Stem Cells
- 1 November 2012
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 132 (11) , 2522-2533
CD133 Is a Marker for Long-Term Repopulating Murine Epidermal Stem Cells
- 1 March 2012
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 132 (3) , 797-810
25 Years of Epidermal Stem Cell Research
- 1 March 2012
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 132 (3) , 797-810
25 Years of Epidermal Stem Cell Research
- 7 April 2011
- Published by Wiley in Journal of Surgical Oncology
- Vol. 103 (6) , 555-557
The role of stem and circulating cells in cancer metastasis
While many solid tumors have been reported to contain stem cell‐like cells termed cancer stem cells, the case for a melanoma stem cell has been debated over the last few years. Herein, we summarize current knowledge of melanoma‐initiating cells and provide an update on recently gained knowledge regarding cancer stem cells and melanoma. J. Surg. Oncol. 2011;103:555–557.
- 7 April 2011
- Published by Wiley in Journal of Surgical Oncology
- Vol. 103 (6) , 555-557
The role of stem and circulating cells in cancer metastasis
While many solid tumors have been reported to contain stem cell‐like cells termed cancer stem cells, the case for a melanoma stem cell has been debated over the last few years. Herein, we summarize current knowledge of melanoma‐initiating cells and provide an update on recently gained knowledge regarding cancer stem cells and melanoma. J. Surg. Oncol. 2011;103:555–557.
- 1 December 2010
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 130 (12) , 2799-2808
Selection of Tumorigenic Melanoma Cells Using ALDH
- 1 December 2010
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 130 (12) , 2799-2808
Selection of Tumorigenic Melanoma Cells Using ALDH
- 1 January 2010
- Published by Springer Nature
- p. 191-199
Aging of Epidermal Stem Cells